Epoetin Alfa and Outcomes in Dialysis amid Regulatory and Payment Reform

Erythropoiesis-stimulating agents (ESAs) are commonly used to treat anemia in patients with CKD, including those receiving dialysis, although clinical trials have identified risks associated with ESA use. We evaluated the effects of changes in dialysis payment policies and product labeling institute...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Am Soc Nephrol
Main Authors: Chertow, Glenn M., Liu, Jiannong, Monda, Keri L., Gilbertson, David T., Brookhart, M. Alan, Beaubrun, Anne C., Winkelmayer, Wolfgang C., Pollock, Allan, Herzog, Charles A., Ashfaq, Akhtar, Sturmer, Til, Rothman, Kenneth J., Bradbury, Brian D., Collins, Allan J.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Nephrology 2016
Assuntos:
Clinical Epidemiology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5042674/
https://ncbi.nlm.nih.gov/pubmed/26917691
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1681/ASN.2015111232
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados